Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Clinic advantages

The ZOE cement is easy to mix and a greater amount of powder can be incorporated into this cement (5 1 by mass) than any other, where even 4 1 by mass is unusual. Because the ZOE cement is sensitive to moisture it can be formulated to have a long working time under normal room conditions (23 °C, relative humidity 50 %) and a rapid set once placed in the warm and moist conditions of the mouth. This is a considerable clinical advantage, making it convenient to use. The cement can be used in a war pack for use on the battlefield. Nevertheless, sensitiveness to humidity can give rise to problems in use under tropical conditions. [Pg.333]

Hydrolytic decomposition of these cements is clinically advantageous. Free calcium hydroxide is present in excess so that large amounts of calcium are released which, together with high alkalinity, promotes... [Pg.350]

Slow dissociation of this binary complex can provide some unique clinical advantages for inhibitors that display this property. [Pg.178]

The very slow dissociation rates for tight binding inhibitors offer some potential clinical advantages for such compounds, as described in detail in Chapter 6. Experimental determination of the value of k, can be quite challenging for these inhibitors. We have detailed in Chapters 5 and 6 several kinetic methods for estimating the value of the dissociation rate constant. When the value of kofS is extremely low, however, alternative methods may be required to estimate this kinetic constant. For example, equilibrium dialysis over the course of hours, or even days, may be required to achieve sufficient inhibitor release from the El complex for measurement. A significant issue with approaches like this is that the enzyme may not remain stable over the extended time course of such experiments. In some cases of extremely slow inhibitor dissociation, the limits of enzyme stability will preclude accurate determination of koff the best that one can do in these cases is to provide an upper limit on the value of this rate constant. [Pg.194]

POTENTIAL CLINICAL ADVANTAGES OF TIGHT BINDING INHIBITORS... [Pg.206]

Potential Clinical Advantages of Tight Binding Inhibitors 207... [Pg.207]

All these aspects of tight binding inhibition can potentially offer important advantages in terms of clinical efficacy, dosing interval, and patient safety (see Swinney, 2004, for an excellent review of some of the clinical advantages of tight binding inhibition and other nonclassical inhibition mechanisms). [Pg.209]

Potential Clinical Advantages of Mechanism-Based Inactivators... [Pg.235]

Potassium-sparing diuretics act on the late portion of the distal tubule and on the cortical collecting duct. As a result of their site of action, these diuretics also have a limited effect on diuresis compared to the loop diuretics (3% of the filtered Na+ ions may be excreted). However, the clinical advantage of these drugs is that the reabsorption of K+ ions is enhanced, reducing the risk of hypokalemia. [Pg.325]

Thyroglobulin is a purified hog-gland extract that is standardized biologically to give a T4 T3 ratio of 2.5 1. It has no clinical advantages and is not widely used. [Pg.249]

Whether the pharmacodynamic advantages of dutasteride confer clinical advantages over finasteride is unknown. Dutasteride inhibits types I and II 5a-reductase, whereas finasteride inhibits only type II. Dutasteride more quickly and completely suppresses intraprostatic DHT (vs. 80% to 90% for finasteride) and decreases serum DHT by 90% (versus 70%). [Pg.947]

DJ-1461 (XVIII), a hydrazone of hydralazine, is claimed to cause considerably less tachycardia (8). To date it has not been shown that any of these compounds has a significant clinical advantage over hydralazine and therefore, over the last twenty-five years, slight modifications of the hydralazine structure have not produced a better drug of this type. [Pg.58]

It has been claimed [201] that this ability to block sympathetic function without major depletion of transmitter is a clinical advantage, especially in maintenance of adequate cardiac function. It is difficult to see, however, how such a point can be valid since catecholamines locked in storage can no more influence cardiac function than can the traces remaining after extensive depletion. [Pg.28]

It remains to be seen whether pan-HDAC inhibition is a prerequisite for clinical efficacy, or whether more subtype-specific HDAC inhibition offers clinical advantages in relation to efficacy and/or toxicity. It should be understood however that the current state of the art suggests that chromatin remodeling is not the only way in which HDACi exert their antitumor effects. As more and more evidence indicates that HDACs not only play a central role in the epigenetic status of chromatin, but are also involved in other levels of enzymatic control, their ability to act on multiple molecular pathways only adds to their multi-targeting properties. [Pg.324]

Liposomal encapsulation or incorporation in a lipid complex can substantially affect a drug s functional properties relative to those of the unencapsulated or nonlipid-associated drug. Lipid-based formulations increase the circulation time and alter the biodistribution of associated amphotericin. Increasing drug levels at site of action and reducing levels in normal tissues offers 2 distinct clinical advantages An increased therapeutic index and altered toxicity profile relative to free drug. [Pg.1667]


See other pages where Clinic advantages is mentioned: [Pg.183]    [Pg.184]    [Pg.433]    [Pg.49]    [Pg.50]    [Pg.379]    [Pg.23]    [Pg.741]    [Pg.130]    [Pg.128]    [Pg.63]    [Pg.68]    [Pg.139]    [Pg.153]    [Pg.207]    [Pg.215]    [Pg.235]    [Pg.247]    [Pg.153]    [Pg.519]    [Pg.5]    [Pg.229]    [Pg.224]    [Pg.15]    [Pg.61]    [Pg.317]    [Pg.698]    [Pg.63]   
See also in sourсe #XX -- [ Pg.175 , Pg.179 , Pg.180 , Pg.196 ]




SEARCH



© 2024 chempedia.info